Evidence map›Paper›PMID 40206272›Full record

ArticleJournal of clinical and translational hepatology2025

Chao Shi, Jingjing Yu, Ziang Meng, Dongxu Lu, Haoran Ding, Haijun Sun, Guangxin Shi, Dongbo Xue, Xianzhi Meng

Abstract read
In one paragraph

Article in Journal of clinical and translational hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Gut fungi exacerbates gallstone formation by activating neutrophil extracellular traps in the liver.Apoptosis : an international journal on programmed cell death · 2026
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chao ShiDepartment of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Jingjing YuDepartment of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Ziang MengDepartment of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Dongxu LuDepartment of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Haoran DingDepartment of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Haijun SunDepartment of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Guangxin ShiDepartment of Internal Medicine, The Third Hospital of Changtu County, Tieling, Liaoning, China.
Dongbo XueDepartment of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Xianzhi MengDepartment of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.ORCID https://orcid.org/0000-0003-3409-4693

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: Cholesterol synthesis and gallstone formation are promoted by trimethylamine-N-oxide (TMAO), a derivative of trimethylamine, which is a metabolite of gut microbiota. However, the underlying mechanisms of TMAO-induced lithogenesis remain incompletely understood. This study aimed to explore the specific molecular mechanisms through which TMAO promotes gallstone formation. Methods: Enzyme-linked immunosorbent assays were used to compare serum concentrations of TMAO, apolipoprotein A4 (APOA4), and proprotein convertase subtilisin/kexin type 9 (PCSK9) between patients with cholelithiasis and normal controls. A murine model of TMAO-induced cholelithiasis was employed, incorporating assays of gallstone weight and bile cholesterol content, along with RNA sequencing of murine hepatic tissue. A TMAO-induced AML12 hepatocyte line was constructed and transfected with targeted small interfering RNAs and overexpression plasmids. Results: Serum TMAO and PCSK9 levels were elevated, whereas APOA4 levels were reduced in patients with cholelithiasis. Furthermore, our murine model demonstrated that TMAO upregulated hepatic expression of PCSK9, 3-hydroxy-3-methylglutaryl-CoA reductase, and ATP-binding cassette sub-family G member 5/8, while reducing APOA4 expression, thereby modulating cholesterol metabolism and promoting lithogenesis. Conclusions: TMAO upregulated hepatic

Indexed as

APOA4CholelithiasisCholesterol metabolismFeedback loopPCSK9TMAO

Identifiers

PMID40206272
PMCPMC11976434

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.